会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • EARLY DETECTION AND PROGNOSIS OF COLON CANCERS
    • 早期检测和预防结肠癌
    • WO2008100913A3
    • 2008-12-18
    • PCT/US2008053689
    • 2008-02-12
    • UNIV JOHNS HOPKINSONCOMETHYLOME SCIENCES SABAYLIN STEPHEN BSCHUEBEL KORNEL ECRIEKINGE WIM VAN
    • BAYLIN STEPHEN BSCHUEBEL KORNEL ECRIEKINGE WIM VAN
    • C12Q1/68C07H21/04C12P19/34
    • C12Q1/6886C12Q2523/125C12Q2600/106C12Q2600/154
    • We have developed a transcriptome-wide approach to identify genes affected by promoter CpG island hypermethylation and transcriptional silencing in colorectal cancer (CRC). By screening cell lines and validating tumor specific hypermethylation in a panel of primary human CRC samples, we estimate that nearly 5% of all known genes may be promoter methylated in an individual tumor. When directly compared to gene mutations, we find a much larger number of genes hypermethylated in individual tumors, and much higher frequency of hypermethylation within individual genes harboring either genetic or epigenetic changes. Thus, to enumerate the full spectrum of alterations in the human cancer genome, and facilitate the most efficacious grouping of tumors to identify cancer biomarkers and tailor therapeutic approaches, both genetic and epigenetic screens should be undertaken. The genes we identified can be used inter alia diagnostically to detect cancer, pre-cancer, and likelihood of developing cancer.
    • 我们已经开发了一种转录组范围的方法来鉴定受启动子CpG岛高甲基化和转录沉默在结肠直肠癌(CRC)中影响的基因。 通过筛选细胞系并验证一组原代人CRC样品中的肿瘤特异性高甲基化,我们估计所有已知基因中的近5%可能是单个肿瘤中的启动子甲基化。 当与基因突变直接比较时,我们发现在个体肿瘤中超甲基化的基因数量更多,并且在具有遗传或表观遗传变化的个体基因内的高甲基化频率高得多。 因此,为了列举人类癌症基因组中的全部变化,并促进最有效的肿瘤分组以鉴定癌症生物标志物并定制治疗方法,应进行遗传和表观遗传筛选。 我们确定的基因可以用于诊断上检测癌症,癌前病症和发展癌症的可能性。
    • 2. 发明申请
    • EARLY DETECTION AND PROGNOSIS OF COLON CANCERS
    • 结肠癌的早期发现和预后
    • WO2008100913A2
    • 2008-08-21
    • PCT/US2008/053689
    • 2008-02-12
    • THE JOHNS HOPKINS UNIVERSITYONCOMETHYLOME SCIENCES SABAYLIN, Stephen, B.SCHUEBEL, Kornel, E.CRIEKINGE, Wim, Van
    • BAYLIN, Stephen, B.SCHUEBEL, Kornel, E.CRIEKINGE, Wim, Van
    • C12Q1/68A61K31/7088A61P35/00
    • C12Q1/6886C12Q2523/125C12Q2600/106C12Q2600/154
    • We have developed a transcriptome-wide approach to identify genes affected by promoter CpG island hypermethylation and transcriptional silencing in colorectal cancer (CRC). By screening cell lines and validating tumor specific hypermethylation in a panel of primary human CRC samples, we estimate that nearly 5% of all known genes may be promoter methylated in an individual tumor. When directly compared to gene mutations, we find a much larger number of genes hypermethylated in individual tumors, and much higher frequency of hypermethylation within individual genes harboring either genetic or epigenetic changes. Thus, to enumerate the full spectrum of alterations in the human cancer genome, and facilitate the most efficacious grouping of tumors to identify cancer biomarkers and tailor therapeutic approaches, both genetic and epigenetic screens should be undertaken. The genes we identified can be used inter alia diagnostically to detect cancer, pre-cancer, and likelihood of developing cancer.
    • 我们开发了转录组范围的方法来鉴定受启动子CpG岛超甲基化和转录沉默影响的结肠直肠癌(CRC)中的基因。 通过筛选细胞系并验证一组原发性人类CRC样品中的肿瘤特异性超甲基化,我们估计所有已知基因中接近5%可能是在个体肿瘤中甲基化的启动子。 当直接与基因突变相比时,我们发现个体肿瘤中超甲基化的基因数量大得多,并且在个体基因内高甲基化的频率高出遗传或表观遗传变化。 因此,为了列举人类癌症基因组的全部改变,并促进最有效的肿瘤分组来鉴定癌症生物标志物和定制治疗方法,应进行遗传和表观遗传学筛选。 我们确定的基因可以用于诊断癌症,癌症前期和发展癌症的可能性等。